Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin versus Tavanex prophylaxis in TURP surgery
IRCT20160514027893N4Phase 3Completed
- Sponsor
- North Khorasan University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cefazolin and levofloxacin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by North Khorasan University of Medical Sciences. Primary endpoints: Body temperature at 48 hours after surgery, Urine culture at 48 hours after surgery and 2 more. Started Apr 2020; status: completed.
02
Drugs
cefazolinlevofloxacin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20160514027893N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160514027893N4.